Paramount Group, Inc. (PGRE) Analysts See $0.23 EPS; Biondvax Pharmaceuticals LTD. – American Depositar (BVXV) Shorts Up By 115.38%

April 20, 2018 - By Ellis Scott

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Logo

Biondvax Pharmaceuticals LTD. – American Depositar (NASDAQ:BVXV) had an increase of 115.38% in short interest. BVXV’s SI was 5,600 shares in April as released by FINRA. Its up 115.38% from 2,600 shares previously. With 7,600 avg volume, 1 days are for Biondvax Pharmaceuticals LTD. – American Depositar (NASDAQ:BVXV)’s short sellers to cover BVXV’s short positions. The SI to Biondvax Pharmaceuticals LTD. – American Depositar’s float is 0.13%. The stock increased 10.65% or $0.66 during the last trading session, reaching $6.86. About 843 shares traded. BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has risen 8.43% since April 20, 2017 and is uptrending. It has underperformed by 3.12% the S&P500.

Analysts expect Paramount Group, Inc. (NYSE:PGRE) to report $0.23 EPS on May, 3.They anticipate $0.01 EPS change or 4.55% from last quarter’s $0.22 EPS. PGRE’s profit would be $60.73 million giving it 15.14 P/E if the $0.23 EPS is correct. After having $0.22 EPS previously, Paramount Group, Inc.’s analysts see 4.55% EPS growth. The stock decreased 1.07% or $0.15 during the last trading session, reaching $13.93. About 392,425 shares traded. Paramount Group, Inc. (NYSE:PGRE) has declined 12.23% since April 20, 2017 and is downtrending. It has underperformed by 23.78% the S&P500.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company has market cap of $1.79 billion. The Company’s product candidate includes M-001, a synthetic peptide protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. It currently has negative earnings.

Headquartered in New York City, Paramount Group, Inc. is a fully-integrated real estate investment trust that owns, operates, manages, acquires and redevelops high-quality, Class A office properties located in select central business district submarkets of New York City, Washington, D.C. and San Francisco. The company has market cap of $3.68 billion.

Among 10 analysts covering Paramount Group (NYSE:PGRE), 3 have Buy rating, 2 Sell and 5 Hold. Therefore 30% are positive. Paramount Group had 20 analyst reports since August 10, 2015 according to SRatingsIntel. Wells Fargo upgraded the shares of PGRE in report on Tuesday, December 13 to “Outperform” rating. The firm earned “Neutral” rating on Tuesday, March 29 by Bank of America. The rating was upgraded by Capital One to “Overweight” on Wednesday, March 2. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, December 13. Goldman Sachs upgraded the shares of PGRE in report on Tuesday, February 6 to “Hold” rating. As per Tuesday, November 10, the company rating was upgraded by Goldman Sachs. The stock of Paramount Group, Inc. (NYSE:PGRE) earned “Market Perform” rating by Cowen & Co on Monday, March 28. The firm has “Buy” rating given on Monday, July 18 by Deutsche Bank. The stock of Paramount Group, Inc. (NYSE:PGRE) has “Hold” rating given on Monday, August 10 by Evercore. The stock has “Sell” rating by Goldman Sachs on Thursday, June 22.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: